, ,

Pressure BioSciences
View On Demand

Transforming A Successful Product Into A Platform Technology

About the Event

Pressure BioSciences (OTC: PBIO) was the first company to safely bring super high pressure to research and manufacturing labs with the introduction of their innovative Pressure Cycling Technology (PCT) platform. Currently in use in over 200 academic, government, pharmaceutical, and biotech research labs around the world, the company has leveraged that expertise to create a full line of pressure-based technologies to benefit businesses in a wide range of industries.
PressureBio’s three platforms include:

  • Pressure Cycling Technology: Used for the development of biopharmaceuticals, biomarker discovery, forensics and anti-bioterror research. Customers include: FDA, CDC, FBI, USDA, Harvard, Stanford, Cedars Sinai, MD Anderson Cancer Center, Sanofi, Genentech, Merck, Roche and others.
  • BaroFold Services: Used to accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. Revenues from the sale and licensing of BaroFold have nearly tripled since last year and the company continues to see increased demand for the platform.
  • Ultra Sheer Technology (UST): Imagine housepaint that never needs stirring. Milk that can sit on the shelf without refrigeration for months. CBD extracts that can be precisely dosed.. UST combines pressures as high as 45,000 PSI with PBIO’s patented nano-gap shear valve, which allows manufacturers to turn water insoluble extracts into stable, water-soluble nano-size formulations.

Join this webinar to hear from Pressure BioScience’s CEO, Richard Schumacher, as he talks about the unlimited potential of the company’s expanded portfolio and their newest subsidiary, PBI Agrochem, that uses UST to create organic, environmentally responsible pesticides, herbicides, and fertilizers that deliver the same results as traditional agrochemicals.

Watch On-Demand Webinar


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.